Filtered By:
Condition: Bleeding
Management: National Institutes of Health (NIH)
This page shows you your search results in order of date.
Order by Relevance | Date
Total 77 results found since Jan 2013.
Folate deficiency increases the incidence of dolutegravir-associated foetal defects in a mouse pregnancy model
EBioMedicine. 2023 Aug 14;95:104762. doi: 10.1016/j.ebiom.2023.104762. Online ahead of print.ABSTRACTBACKGROUND: Dolutegravir (DTG) is a recommended first-line regimen for all people with Human Immunodeficiency Virus (HIV) infection. Initial findings from Botswana, a country with no folate fortification program, showed an elevated prevalence of neural tube defects (NTDs) with peri-conceptional exposure to DTG. Here we explore whether a low folate diet influences the risk of DTG-associated foetal anomalies in a mouse model.METHODS: C57BL/6 mice fed a folate-deficient diet for 2 weeks, were mated and then randomly allocated ...
Source: Cancer Control - August 16, 2023 Category: Cancer & Oncology Authors: Haneesha Mohan Jessica Nguyen Ben MacKenzie Audrey Yee Evelyn Yukino Laurette Tanvi Sanghvi Oscar Tejada Valeriya Dontsova Kit-Yi Leung Cameron Goddard Taylor De Young John G Sled Nicholas D E Greene Andrew J Copp Lena Serghides Source Type: research
Thrombectomy vs. medical management for large vessel occlusion strokes with minimal symptoms
Exp Ther Med. 2023 Jun 23;26(2):377. doi: 10.3892/etm.2023.12076. eCollection 2023 Aug.ABSTRACTPatients with acute ischemic stroke (AIS) presenting mild symptoms with a low National Institutes of Health Stroke Scale (NIHSS) score ≤8 and also found to have an intracranial large vessel occlusion (LVO) undergo endovascular thrombolysis (ET) or medical management alone. The current study aimed to evaluate the safety and effectiveness of medical management vs. ET therapy among patients with mild AIS symptoms (NIHSS score ≤8) accompanied by LVO. The present meta-analysis included articles involving mild AIS, LVO, thrombectom...
Source: Experimental and Therapeutic Medicine - July 17, 2023 Category: General Medicine Authors: Iason-Stefanos Anagnostopoulos Vasiliki Epameinondas Georgakopoulou Ilias Trakas Petros Papalexis Nikolaos Trakas Demetrios A Spandidos George Fotakopoulos Source Type: research
New TREMFYA ® (guselkumab) Data Show an Overall Clinical Response Rate of Approximately 80 Percent in a Phase 2b Induction Study of Adults with Moderately to Severely Active Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2b QUASAR Induction Study 1 in adults with moderately to severely active ulcerative colitis (UC) with inadequate responses to previous treatments. The data presented at the 2022 American College of Gastroenterology (ACG) Annual Scientific Meeting show an overall clinical response rate of approximately 80 percent in patients who were randomized to TREMFYA® (guselkumab).Clinical responsea at weeks 12 or 24 of the study was ultimately achieved by 80.2 percent of patients who w...
Source: Johnson and Johnson - October 24, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Colorectal cancer screening with fecal immunochemical testing: a community-based, cross-sectional study in average-risk individuals in Nigeria
This study aimed to assess the fecal immunochemical test as a colorectal cancer screening modality in average-risk individualS in Nigeria.METHODS: A population-based, cross-sectional study of qualitative fecal immunochemical test-based colorectal cancer screening was done in asymptomatic, average-risk participants aged 45-75 years in three states in Nigeria (Osun, Kwara, and Lagos). Participants were invited to enrol using age-stratified and sex-stratified convenience sampling following community outreach. Exclusion criteria included a personal history of colorectal cancer or rectal bleeding in the previous 6 months, a fir...
Source: Cancer Control - June 17, 2022 Category: Cancer & Oncology Authors: Olusegun I Alatise Anna J Dare Patrick A Akinyemi Fatimah B Abdulkareem Samuel A Olatoke Gregory C Knapp T Peter Kingham African Research for Oncology Colorectal Screening Early Detection Group Source Type: research
Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news
